Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Price Down 4.7% - Time to Sell?

Key Points

• Shares fell about 4.7% midday to $11.1083, with only ~1,570 shares traded — an 87% decline versus the average daily volume of 12,405 shares.
• The stock trades near its short- and long-term averages (50-day $11.03, 200-day $10.65), has a market cap of $3.57 billion and an unusually low PE ratio of 0.10.
• Santen is a Japan-based specialty pharmaceutical company focused exclusively on ophthalmology, selling treatments and surgical/diagnostic products for eye diseases like glaucoma, dry eye and retinal disorders.

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY - Get Free Report) was down 4.7% during mid-day trading on Monday . The company traded as low as $11.1083 and last traded at $11.1083. Approximately 1,570 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 12,405 shares. The stock had previously closed at $11.6540.

Santen Pharmaceutical Stock Down 4.7%

The stock's 50 day moving average price is $11.03 and its 200-day moving average price is $10.65. The stock has a market capitalization of $3.57 billion and a PE ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.